KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Short term Debt (2016 - 2025)

Amgen has reported Short term Debt over the past 14 years, most recently at $4.6 billion for Q4 2025.

  • Quarterly results put Short term Debt at $4.6 billion for Q4 2025, up 29.55% from a year ago — trailing twelve months through Dec 2025 was $4.6 billion (up 29.55% YoY), and the annual figure for FY2025 was $4.6 billion, up 29.55%.
  • Short term Debt for Q4 2025 was $4.6 billion at Amgen, up from $2.2 billion in the prior quarter.
  • Over the last five years, Short term Debt for AMGN hit a ceiling of $5.5 billion in Q2 2024 and a floor of $87.0 million in Q4 2021.
  • Median Short term Debt over the past 5 years was $2.2 billion (2023), compared with a mean of $2.5 billion.
  • Biggest five-year swings in Short term Debt: skyrocketed 4651.65% in 2021 and later plummeted 81.11% in 2022.
  • Amgen's Short term Debt stood at $87.0 million in 2021, then soared by 1728.74% to $1.6 billion in 2022, then fell by 9.3% to $1.4 billion in 2023, then skyrocketed by 146.02% to $3.6 billion in 2024, then rose by 29.55% to $4.6 billion in 2025.
  • The last three reported values for Short term Debt were $4.6 billion (Q4 2025), $2.2 billion (Q3 2025), and $2.4 billion (Q2 2025) per Business Quant data.